Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
15 07 2019
Historique:
received: 31 01 2019
revised: 13 03 2019
accepted: 19 03 2019
pubmed: 4 4 2019
medline: 20 12 2019
entrez: 4 4 2019
Statut: ppublish

Résumé

Image guided adaptive brachytherapy (IGABT) for cervical cancer improves pelvic control and survival across all stages. Improvement in pelvic control is larger in advanced stages, but improvement in survival is similar across stages. This paper analyzes the patterns of failure in the RetroEMBRACE cohort to investigate this discrepancy. 731 patients from 12 institutions treated with chemoradiation therapy and magnetic resonance imaging or computed tomography-based IGABT were evaluated. The pattern of failure at time of first relapse was analyzed. Three hundred twenty-five failures (single and synchronous) occurred in 222 of 731 patients (30%). Among the 325 failures, 9% were local and 6% regional. Pelvic (local or regional) failures made up 13%, paraaortic node (PAN) 9%, systemic 21%, and distant (systemic + PAN) 24%. Of the 222 patients with treatment failure, 21% had pelvic failure alone, 57% had distant failure alone, and 23% had both pelvic and distant failure. Of all failures that occurred, 40% to 50% occurred in the first year, with a further 20% to 30% occurring in the second year. Although local, regional, and PAN failure tended to plateau after year 3, systemic failure continued to occur up to year 10. Implementation of IGABT has changed the patterns of relapse after chemoradiation therapy for cervical cancer. The predominant failure after IGABT is systemic, whereas the predominant failure with conventional brachytherapy is pelvic. Effective treatments to eradicate micrometastases in PAN and distant organs are needed in addition to IGABT and chemoradiation therapy to maximize local, regional, PAN, and systemic control and improve survival.

Identifiants

pubmed: 30940530
pii: S0360-3016(19)30565-6
doi: 10.1016/j.ijrobp.2019.03.038
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

895-902

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Li-Tee Tan (LT)

Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals, United Kingdom.

Richard Pötter (R)

Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria.

Alina Sturdza (A)

Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: alina.sturdza@akhwien.at.

Lars Fokdal (L)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Christine Haie-Meder (C)

Radiotherapy Department, Brachytherapy Unit, Gustave Roussy Cancer Campus, Villejuif, France.

Maximilian Schmid (M)

Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria.

Deborah Gregory (D)

Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals, United Kingdom.

Primoz Petric (P)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Institute of Oncology, Division of Radiotherapy, Ljubljana, Slovenia; National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.

Ina Jürgenliemk-Schulz (I)

Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.

Charles Gillham (C)

Department of Radiation Oncology, St Luke's Hospital, Dublin, Ireland.

Eric Van Limbergen (E)

Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium.

Peter Hoskin (P)

Mount Vernon Cancer Center, Northwood, United Kingdom.

Ekkasit Tharavichitkul (E)

Division of Radiation Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

Elena Villafranca (E)

Department of Radiation Oncology, Hospital of Navarra, Pamplona, Spain.

Umesh Mahantshetty (U)

Department of Radiation Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India.

Christian Kirisits (C)

Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria.

Jacob Lindegaard (J)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Kathrin Kirchheiner (K)

Department of Radiation Oncology, Comprehensive Cancer Center, Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria.

Kari Tanderup (K)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH